Forest Road Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRX research report →
About the company
Forest Road Acquisition Corp., established in 2020 and headquartered in New York, New York, is focused on identifying and executing a strategic consolidation with one or more companies. The firm aims to complete various corporate transactions, including mergers, exchanges of capital stock, asset acquisitions, stock purchases, or other forms of corporate restructuring, specifically targeting the technology, media, and telecommunications sectors.
- CEO
- Zachary Tarica
- IPO
- 2020
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on FRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.75B
- P/E
- 6.82
- PEG
- 0.00
- P/S
- 17.08
- P/B
- 2.31
- EV/EBITDA
- 641.86
- Div Yield
- 0.00%
- Gross Margin
- 73.69%
- Op Margin
- 5.91%
- Net Margin
- 5.68%
- ROE
- 39.07%
- ROIC
- 19.51%
Latest fiscal year · YoY change
- Revenue
- $251.73M-39.9%
- Gross Profit
- $183.78M-36.0%
- Op Income
- $5.53M
- Net Income
- $-2,860,000+96.0%
- EPS
- $-0.41+96.1%
- OCF Growth
- +748.9%
- FCF Growth
- +976.3%
- 52W High
- $18.20
- 52W Low
- $9.24
- 50D MA
- $10.29
- 200D MA
- $10.64
- Beta
- 0.00
- Avg Volume
- 1.57M
No earnings-call transcripts are available for FRX yet.
- Free Float
- 33.5%
- Shares Outstanding
- 312.16M
- Float Shares
- 104.54M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 1,527 |
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 20,000 |
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 2,406 |
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 7,815 |
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 5,909 |
| Jul 1, 14 | Francis Perier I Jr | other | 32,636 |
| Jul 1, 14 | Francis Perier I Jr | other | 18,632 |
| Jul 1, 14 | Francis Perier I Jr | sell | 2,482 |
| Jul 1, 14 | Francis Perier I Jr | sell | 31,018 |
| Jul 1, 14 | Francis Perier I Jr | sell | 75,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FRX coverage
Recent articles, reports, and earnings notes.
No research on FRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FRX report →Fennec Pharmaceuticals (TSE:FRX) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened
defenseworld.net · Jul 28
Fennec Announces Results of Annual Meeting
globenewswire.com · Jun 10
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
globenewswire.com · May 21
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · May 18
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 14
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 14
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
globenewswire.com · May 7
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.